Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kyoto Group: Invitation to Capital Markets Day, Thursday 27 October 2022

Oslo, 18 October 2022 - Kyoto Group AS (Kyoto Group) welcomes investors, analysts and journalists to Kyoto Group Capital Markets Day on Thursday 27 October 2022. Event: Kyoto Group Capital Markets Day 2022 Date: 27 October 2022 from 14:00 to 17:00 CEST Place: Klimahuset, Oslo Botanical Gardens, Address: Sars' gate 1, Oslo Speakers: Camilla Nilsson, CEO, Kyoto Group Håvard Haukdal, CFO Kyoto Group Bjarke Buchberg, CTO, Kyoto Group Tim de Haas, Chief Commercial Officer (CCO), Kyoto Group Magnus Rambraut, Commercial Director Nitrates, Yara International Sigbjørn

Notification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä Corporation

Wärtsilä Corporation, Flagging notification, 18 October 2022 at 16:45 EESTNotification in accordance with the Finnish Securities Market Act Chapter 9 § 5: BlackRock, Inc.’s holding in Wärtsilä CorporationBlackRock, Inc. has informed Wärtsilä Corporation that it has crossed above the 5% disclosure limit on total holding in shares and voting rights on 17 October 2022. Following the transaction, BlackRock, Inc. owns 4.86% of Wärtsilä’s shares and voting rights, while its total holding in Wärtsilä Corporation corresponds to 5.03%. Total position of BlackRock, Inc. and its funds subject to

Invitation to Kongsberg Automotive's Q3 2022 Earnings Presentation

Zurich, October 18, 2022: Kongsberg Automotive (KA) will release its Q3 results on Tuesday November 8, 2022 at approximately 07:00 CET. President & CEO Joerg Buchheim and CFO Frank Heffter will present the results during a webcast at 09:00 CET and will host a Q&A session after the presentation. The event is open to the public and will be webcasted live. The following link  includes registration and multiple options to access the webcast: channel.royalcast.com/landingpage/hegnarmedia/20221108_1/ The earnings release and

Scandinavian ChemoTech’s Animal Care division signs exclusive distribution agreement for the Australian and New Zealand market

Vetiqure AB has today entered a strategic collaboration with Gamma Gurus Pty Ltd by signing an exclusive distribution agreement for the Australian and New Zealand veterinary market.After over a 12-month extensive search and evaluation of over 20 potential distributors, we are very happy to announce that our top choice, Gamma Gurus, has now become a part of the Vetiqure family. This distribution agreement will generate one order of at least one vetIQure™ system, which will be activated after local ethics committee approval, before the end of January 2023.   Parallel to this agreement,

Persevere or Perish in Shattered Hope, the Second Expansion for Surviving the Aftermath

Surviving the Aftermath: Shattered Hope makes “moonfall” on November 3rdSTOCKHOLM — October 18, 2022 —  Paradox Interactive and Iceflake Studios today announced Shattered Hope , the second expansion for their survival colony builder, Surviving the Aftermath. Shattered Hope introduces the Shattered Moon calamity, giving players the ability to boost resource production and the task of maintaining survivor’s hope. Surviving the Aftermath: Shattered Hope launches on November 3rd for Xbox One, PlayStation 4, and

Contract award within renewable energy

Solstad Offshore ASA is pleased to announce a contract award for the subsea construction vessel ("CSV") Normand Baltic and a contract extension for the CSV Normand Navigator. The contracts are for renewable energy projects in North Europe and Asia and represents a combined firm utilization of 310 days, with additional options thereafter. Normand Baltic contract will cover the majority of Q4-22 and Q1-2023, while Normand Navigator now has a firm contract to Q4 2023. The contracts have a combined value of approximately NOK 320 million including addition services, such as ROV’s, Walk to

Cyclyx, ExxonMobil and LyondellBasell Advance First-of-its-Kind Plastic Processing Facility in Houston

· Facility will sort and process a wide range of plastic waste designed to produce 150,000 metric tons of feedstock per year for mechanical and advanced recycling · ExxonMobil and LyondellBasell plan to invest an estimated $100 million in the facility with start-up expected in 2024PORTSMOUTH, New Hampshire, USA, October 18, 2022 – Cyclyx International , ExxonMobil and LyondellBasell today announced they have signed an agreement to advance development of a first-of-its-kind plastic waste sorting and processing facility in the Houston area. The new facility addresses a

Publishing of Apetit Plc’s Business Review for January-September 2022

Apetit Plc, Press release, on 18 October 2022 at 16:00 p.m.Publishing of Apetit Plc’s Business Review for January-September 2022 Apetit Plc will publish its Business Review for January-September 2022 on Tuesday 25 October 2022 at 8.30 a.m. A separate press conference in relation to the Business Review will not be arranged.Apetit PlcFor further information, please contact: Miika Kemilä, Communications and Sustainability Manager, 010 402 4044 Apetit is a food industry company firmly rooted in Finnish primary production. Our operations are based on a unique and sustainable value

Elicera Therapeutics enters first international collaboration involving the iTANK platform with a Spanish research institution

Gothenburg, October 18, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced that it has entered a Material Transfer Agreement with the Josep Carreras Leukaemia Research Institute (“JCLRI”) in Spain for use of the iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma. The agreement is the first to be executed as part of Elicera’s strategy of finding collaborators and licensing partners for iTANK.Following

Redsense receives highest value order to date

Redsense Medical has secured its largest single order to date, valued at MSEK 3.7, from one of the company’s US distributors. “We are very excited about this important order for the US market. This large order gives us an excellent start of the fourth quarter. Given the challenging situation during the pandemic and the aftermath, this is a significant step in the right direction. Furthermore, this proves our strong focus on providing patient safety and the confidence that our customers place in our products” says Pontus Nobréus CEO of Redsense Medical AB. “We continue our clear focus

Hit models in polar and petrol

Exhibits a sporty daily routine, a sense of style and, yes, success: the new NOMOS watches in blue and green with metal bracelet. Their names: Club Sport neomatik polar, Club Sport neomatik petrol.GLASHÜTTE, OCTOBER 2022. Club Sport neomatik polar, Club Sport neomatik petrol—the names of two new NOMOS watches the manufacture just unveiled at its annual Forum in Glashütte. These models feature everything that matters on your wrist. Not only are they made by hand in the Glashütte watchmaking tradition, precise and extremely reliable, but they are also robust and beautifully presented. The

Rhovac board member resigns due to health reasons

RhoVac AB (publ) announces today, October 18[th] 2022, that board member and co-founder Anders Ljungqvist is resigning from the board at his own request due to health reasons.Gunnar Gårdemyr, chairman of the board, comments: "On behalf of the board, I would like to give a warm thank you to Anders for his decisive contributions in various roles in the company throughout the years. He has been an inspiration to all of us and it is regrettable but completely understandable that Anders is now forced to focus on his health and family and thus leaves the board's work".

Glaston publishes the January 1– September 30, 2022 Interim Report on Thursday, October 27, 2022 at 8.30

Glaston Corporation   Press release                  18.10.2022 at 15.00Glaston Corporation will publish its January–September 2022 Interim Report on Thursday, October 27, 2022 at around 8.30 a.m. Finnish time. The report and presentation will be available as soon as possible after publishing on the Company’s internet pages at www.glaston.net.Glaston’s CEO Anders Dahlblom and CFO Päivi Lindqvist will present the financial result to analysts, investors and media representatives on the publication day at 11:00 (Finnish time) in English. The live audiocast can be accessed through the link:

Two key recruitments at Fingersoft

The Finnish mobile game studio Fingersoft has appointed Mr. Mika Reini as a new member of its Board of Directors, and Mr. Teemu Väisänen will start in the newly created position of Game Development Technical Director.Mika Reini has worked in the gaming industry for over 20 years and is now an investor and advisor to a number of companies. Reini has previously served on the boards of Remedy and Redhill Games, among others, and currently works as CEO of Dreamboss Ltd. “Thank you to the shareholders of Fingersoft for the trust. I am genuinely looking forward to bringing my experience to the

Publication of a Prospectus

Royal Bank of Canada October 18, 2022 Publication of Prospectus Not for release, publication or distribution, directly or indirectly, in or into the United States. Royal Bank of Canada has agreed to issue EUR40,000,000 1.034 per cent. Senior Notes due January 25, 2034 (to be consolidated and form a single series with EUR450,000,000 1.034 per cent. Senior Notes due January 25, 2034 issued on January 25, 2022), Series 64148 (the "Notes") pursuant to its Programme for the Issuance of Securities (the "Programme"). The following document constitutes the final terms dated October

Advenica receives an order worth MSEK 3 from a Swedish authority

Advenica has received a new order from a Swedish authority. The deal is worth MSEK 3, refers to services and deliveries will take place continuously during 2022 and 2023.Advenica has extensive experience in working with customers who place very high demands on security technology – customers who demand solutions that protect the most sensitive information A new order for services such as maintenance, threat intelligence and further development linked to previously delivered network segmentation systems has now been received from a Swedish authority. Delivery of the order will take place

Klimator extends and expands business in Finland

Klimator extends agreement and expands the business in winter maintenance in Finland together with its partner Autori to an order value of 700 KSEK for the coming winter. In short the agreement means continued trust and an expanded geographic delivery and extension of the completed Proof-of-Concept with high-resolution road condition forecasts in order to conduct more efficient winter road management.“We are very happy about the trust to extend and expand the agreement covering our mutual customers in Finland. Autori has a strong position in Finland, knowing the market and the industry well.

Olvi Changes Its Near-Term Outlook

Olvi plc       Inside information 18 October 2022 at 2.30 pm   Olvi Changes Its Near-Term Outlook   The operating profit from continuing operations in 2022 is expected to decrease from the previous year.   Costs arising from raw materials, packaging materials, energy and logistics are increasing at an exceptionally high rate, and there are challenges with availability. The increase in costs is expected to continue in the near future. It has not yet been possible to fully transfer the cost increases to sales prices, especially in Finland and Denmark.     Olvi

Holding(s) in Company

TR-1: Standard form for notification of major holdings   NOTIFICATION OFMAJOR HOLDINGS(tobe sent to therelevant issuerandto the FCA inMicrosoft Wordformatif possible) i 1a. Identity of Faron Pharmaceuticalsthe issuer or the Ltdunderlying issuerof existingsharesto which votingrights areattachedii:1b. Pleaseindicate if theissuer isa non-UK issuer (please markwithan “X” ifappropriate)Non-UK issuer X2. Reason for thenotification(please mark the

FIA Smart Driving Challenge Subevent ‘Drive Well Challenge —powered by Garmin’ to enable the study of the relationship between driver health and road risk

The FIA Smart Driving Challenge (FIA SDC), created by the Fédération Internationale de l'Automobile (FIA) and global provider of DriverDNA data analytics Greater Than, is launching a new three-month Subevent with official FIA Smart Driving Challenge Timing Partner Garmin. Designed to improve driver awareness and encourage safe driving habits, the ‘Drive Well Challenge – powered by Garmin’ will enable Greater Than to conduct a study on the relationship between driver health and road risk.The ‘Drive Well Challenge – powered by Garmin’, will take place from 18 October 2022 to 17 January 2023

Eevia Health Plc receives a 1 MSEK/96 KEUR sales order for a Bilberry extract product

Eevia Health Plc, (”Eevia” or ”The Company”), has received a 96 KEUR sales order from a European nutraceutical brand owner.The customer is a European brand owner headquartered in Sweden. The customer is marketing its consumer products in over 50.000 pharmacies, health food shops, and other retail outlets across 36 countries, including China and USA. The sales value to Eevia of this new order is c. 96 000 EUR. The product is a Bilberry extract standardized for anthocyanins and is a repeat order. This is one of the customers Eevia services without using a distributor. The business has been

ProTrans cell therapy maintains insulin production effect 3.5 years after treatment

NextCell Pharma AB ("NextCell" or the "Company") today announces that type-1 diabetes patients receiving two treatments with a high dose of ProTrans cell therapy maintain a significantly higher endogenous insulin production than patients treated with low or medium doses.Type I diabetes patients enrolled in the ProTrans Repeat Study, treated with the highest dose of ProTrans, maintained a significantly higher preserved endogenous insulin production than patients treated with low and medium doses (p<0.05). On average, the 3 patients treated in each of the low, medium and high-dose cohorts

There are no items matching the current filter
There are no more items matching the current filter
Back to top